16 completed, 4 terminated, 2 withdrawn. 22 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 16, Terminated 4, Withdrawn 2 |
| Phase 2 | 5 | Completed 5 |
Follow Recurrent Squamous Cell Carcinoma of the Larynx: new trials by email Literature Review of Recurrent Squamous Cell Carcinoma of the Larynx trials Research Report on Recurrent Squamous Cell Carcinoma of the Larynx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck sorafenib tosylate, cisplatin, docetaxel - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 3 | 2014-04-14 | 2018-05-24 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy entolimod, intensity-modulated radiation therapy, cisplatin - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2014-01-01 | 2013-12-11 | |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Completed | University of Chicago | 48 | 2013-03-26 | 2024-07-31 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer talactoferrin, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | Stanford University | 4 | 2012-05-01 | 2016-08-02 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy everolimus, erlotinib hydrochloride, biopsy - Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer | Phase 1 | Withdrawn | Fox Chase Cancer Center | 2011-04-01 | 2023-04-04 | |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2008-07-01 | 2013-07-02 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer HPPH, photodynamic therapy, conventional surgery - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Roswell Park Cancer Institute | 15 | 2006-10-19 | 2022-07-25 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-07-01 | 2013-04-10 |
| Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck PV701 - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2004-04-01 | 2013-01-24 |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck erlotinib hydrochloride, pharmacological study, pharmacogenomic studies - Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 80 | 2003-04-01 | 2013-01-09 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis - Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 58 | 2003-03-01 | 2018-10-02 |
| Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer erlotinib hydrochloride, docetaxel, laboratory biomarker analysis - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2002-10-01 | 2013-11-25 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction erlotinib hydrochloride, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 2001-12-01 | 2013-01-16 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2001-12-01 | 2013-09-30 |
Showing 20 of 22. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (22) · Salivary Gland Neoplasms (19) · Tongue Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (8) · Esthesioneuroblastoma, Olfactory (8) · Colonic Neoplasms (7) · Carcinoma, Ovarian Epithelial (6) · Anus Neoplasms (5) · Breast Neoplasms (5) · Esophageal Neoplasms (5) · Pancreatic Neoplasms (5) · Rectal Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4) · Prostatic Neoplasms (4)
Carcinoma (22) · Head and Neck Neoplasms (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Neoplasms by Site (22) · Neoplasms, Glandular and Epithelial (22) · Carcinoma, Squamous Cell (21) · Mouth Diseases (20) · Mouth Neoplasms (20) · Stomatognathic Diseases (20) · Salivary Gland Diseases (19) · Tongue Diseases (10) · Digestive System Diseases (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9)
Erlotinib Hydrochloride (7) · Cetuximab (6) · Bevacizumab (3) · Carboplatin (2) · Cisplatin (2) · Docetaxel (2) · Everolimus (2) · Fluorouracil (2) · Hydroxyurea (2) · Pharmacogenomic Testing (2) · Radiation (2) · Radiotherapy (2) · Taxes (2) · 1-phenyl-3,3-dimethyltriazene (1) · 130-nm albumin-bound paclitaxel (1)
National Cancer Institute (NCI) (12) · Fox Chase Cancer Center (2) · Roswell Park Cancer Institute (2) · University of Chicago (2) · AIDS Malignancy Consortium (1) · Ohio State University Comprehensive Cancer Center (1) · Stanford University (1) · University of Washington (1)
United States (21)
Tanguy Seiwert (2) · Alain Mita (1) · Antonius Miller (1) · Anurag Singh (1) · Barbara Burtness (1) · Charles Rudin (1) · David Gustin (1) · David Solit (1) · Eric Kraut (1) · Everett Vokes (1) · Hassan Arshad (1) · Heather Wakelee (1) · Jonas de Souza (1) · Laura Chow (1) · Laura Goff (1)
PMID 19201650, PMID 23868427, PMID 26928328, PMID 35429391, PMID 35945244
N01CM62201 (2), U01CA076576 (2), N01CM17102 (1), P30CA014599 (1), P30CA015704 (1), P30CA044579 (1), P30CA054174 (1), P30CA068485 (1), U01CA069852 (1), U01CA069853 (1), U01CA069856 (1), U01CA070095 (1), U01CA121947 (1), U10CA031946 (1)